CRIS Current Research Information System

BON, ISABELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.669
AS - Asia 3.693
EU - Europa 2.747
AF - Africa 267
Continente sconosciuto - Info sul continente non disponibili 241
SA - Sud America 226
OC - Oceania 7
AN - Antartide 1
Totale 11.851
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.600
SG - Singapore 1.054
VN - Vietnam 1.017
CN - Cina 826
GB - Regno Unito 571
IT - Italia 491
SE - Svezia 443
DE - Germania 348
HK - Hong Kong 280
FR - Francia 188
BR - Brasile 176
IN - India 162
RU - Federazione Russa 137
IE - Irlanda 123
TG - Togo 110
NL - Olanda 105
UA - Ucraina 97
BD - Bangladesh 82
ZA - Sudafrica 56
JP - Giappone 51
EE - Estonia 45
FI - Finlandia 42
CA - Canada 38
JO - Giordania 38
NG - Nigeria 35
BG - Bulgaria 33
TH - Thailandia 30
CI - Costa d'Avorio 29
BE - Belgio 25
PH - Filippine 24
CH - Svizzera 21
ID - Indonesia 20
AR - Argentina 19
KR - Corea 17
AT - Austria 16
PL - Polonia 16
MX - Messico 15
SC - Seychelles 13
ES - Italia 11
IQ - Iraq 11
TW - Taiwan 10
IR - Iran 9
TR - Turchia 9
MY - Malesia 8
SA - Arabia Saudita 8
PK - Pakistan 7
PT - Portogallo 7
UZ - Uzbekistan 7
CL - Cile 6
CO - Colombia 6
EC - Ecuador 6
VE - Venezuela 6
AU - Australia 5
LB - Libano 5
PE - Perù 5
RO - Romania 5
CZ - Repubblica Ceca 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CY - Cipro 3
EG - Egitto 3
EU - Europa 3
GR - Grecia 3
HN - Honduras 3
LV - Lettonia 3
MA - Marocco 3
AL - Albania 2
BS - Bahamas 2
BZ - Belize 2
CG - Congo 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
GT - Guatemala 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
MD - Moldavia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
SI - Slovenia 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BH - Bahrain 1
BJ - Benin 1
GI - Gibilterra 1
HR - Croazia 1
HU - Ungheria 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MG - Madagascar 1
MS - Montserrat 1
NP - Nepal 1
OM - Oman 1
Totale 11.606
Salva come PNG Salva come JPEG
Città #
Singapore 754
Ashburn 524
Southend 484
Fairfield 395
Chandler 337
San Jose 287
Hong Kong 263
Ho Chi Minh City 239
Santa Clara 235
Hanoi 217
Woodbridge 209
Seattle 191
Wilmington 170
Houston 168
Ann Arbor 164
Dong Ket 148
Princeton 138
Cambridge 135
Beijing 129
Dublin 123
Lomé 110
Boardman 102
Bologna 96
Council Bluffs 82
Florence 72
Lauterbourg 66
Nanjing 60
Los Angeles 58
Westminster 54
Jacksonville 52
Padova 49
Berlin 45
New York 43
Turin 40
Amman 38
Tokyo 38
Da Nang 36
Buffalo 34
Abeokuta 33
Sofia 33
São Paulo 33
Munich 32
Jinan 31
Milan 31
Redondo Beach 31
Shenyang 30
Abidjan 29
San Diego 27
Helsinki 26
Redmond 26
Hefei 25
Brussels 24
Saint Petersburg 24
Dallas 23
Rome 23
Guangzhou 22
Hebei 22
Frankfurt am Main 21
Haiphong 21
Tianjin 21
Phoenix 20
Chicago 19
Zhengzhou 19
Dearborn 16
Des Moines 16
Shanghai 16
Bremen 15
Hangzhou 15
Nanchang 15
The Dalles 15
Changsha 14
Ningbo 14
Atlanta 13
Jiaxing 13
London 13
Nuremberg 13
Olalla 13
Bern 12
Falls Church 12
Jakarta 12
Orem 12
Bangkok 11
Falkenstein 11
Montreal 11
Toronto 11
Turku 11
Can Tho 10
Hải Dương 10
Mülheim 10
Taizhou 10
Warsaw 10
Bühl 9
Haikou 9
Shenzhen 9
Thái Nguyên 9
Wuhan 9
Yubileyny 9
Amsterdam 8
Brooklyn 8
Paris 8
Totale 7.463
Salva come PNG Salva come JPEG
Nome #
Restriction Factors expression decreases in HIV-1 patients after cART 280
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 270
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells 246
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 243
Discordant resistance interpretations in multi-treated HIV-1 patients 240
Acute onset myopericarditis as unusual presentation of primary HIV infection 240
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 237
Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection 229
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 223
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 213
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 208
HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. 207
Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke 199
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 197
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 196
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. 196
Effects of Antiretroviral Molecules on Survival and Gene Expression of an Osteoblast-like Cell Line 195
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 191
Antiretroviral molecules and cardiovascular diseases. 190
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures 187
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 185
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 184
Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. 184
Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. 183
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 179
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. 175
HIV and kidney: A dangerous liaison 174
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 173
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 172
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 171
Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. 170
HIV-related mechanisms in atherosclerosis and cardiovascular diseases. 168
Human T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological results 168
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case report. 168
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns 167
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 166
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 165
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 162
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 162
HIV-1 gp120 impairs the differentiation and survival of cord blood CD34+ HPCs induced to the erythroid lineage. 161
Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy 156
V3 net charge: additional tool in HIV-1 tropism prediction 153
An HIV type 2 case series in Italy: A phylogenetic analysis 149
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 148
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 148
Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy 145
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. 144
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 143
Do the HIV-1 subtypes circulating in Italy resemble the Red Queen running in Carroll's novel? 139
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy 136
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. 133
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. 132
Significant association between statin-associated myalgia and Vitamin D deficiency among treated HIV-infected patients 130
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study) 129
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 128
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 127
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. 126
HBsAg seroreversion in HBsAg-negative/HBcAb-positive patients with HIV infection treated with direct-acting antivirals for HCV: A retrospective study 126
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: Results from the DIVA study group 125
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir 123
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 120
Improving counterfactual reasoning with kernelised dynamic mixing models 119
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy 115
null 113
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. 111
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 103
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine. 102
Hepatitis A virus in a medical setting in Madagascar: a lesson for public health 101
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 100
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir. 89
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir 81
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia. 78
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 55
Totale 11.851
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.858
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.858
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.304 0 75 66 147 103 62 31 107 57 230 252 174
2022/20231.577 142 231 59 193 138 96 38 100 271 57 171 81
2023/2024404 25 66 39 52 31 81 19 24 9 29 21 8
2024/20251.602 72 247 133 129 295 90 73 40 19 129 55 320
2025/20263.765 335 320 260 250 391 222 437 207 815 271 163 94
2026/2027180 73 107 0 0 0 0 0 0 0 0 0 0
Totale 11.851